Work Here?
Nomic
Work Here?
Develops advanced proteomics solutions using nanotechnology
Nomic
Work Here?
Develops advanced proteomics solutions using nanotechnology
About Nomic
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$58.4M
Headquarters
Montreal, Canada
Founded
2017
Overview
Nplex Biosciences develops advanced solutions for protein measurement in the biotechnology sector, focusing on proteomics using nanotechnology. Their main product, the nELISA, is a compact and efficient version of the traditional sandwich ELISA immunoassay, designed to measure proteins in a scalable and cost-effective manner. This platform allows researchers to conduct high-throughput protein profiling, which is essential for projects in drug discovery, biomarker discovery, and personalized medicine. Nplex Biosciences differentiates itself from competitors by utilizing DNA nanotechnology to analyze proteins on tiny beads, providing precise results while reducing costs. The company's goal is to offer a reliable and scalable proteomics platform that meets the needs of academic institutions, pharmaceutical companies, and biotech firms.
Simplify's Take
What believers are saying
- Nomic secured $42M in Series B funding to expand commercial operations.
- Growing demand for personalized medicine boosts interest in Nomic's proteomics solutions.
- Collaborative research initiatives offer opportunities to expand Nomic's client base.
What critics are saying
- Emerging biotech startups may dilute Nomic's market share.
- Rapid technological advancements could render Nomic's platform obsolete.
- Supply chain vulnerabilities could disrupt production and delivery schedules.
What makes Nomic unique
- Nomic's nELISA platform offers scalable, cost-effective protein measurement solutions.
- The company leverages DNA nanotechnology for precise protein analysis on micron-sized beads.
- Nomic serves high-throughput needs in drug discovery and personalized medicine sectors.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$58.4M
Above
Industry Average
Funded Over
3 Rounds
Industry standards
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↓ -6%2 year growth
↓ -6%MONTREAL, September 17, 2024--Nomic Bio ("Nomic"), the Protein Profiling company, today announces the completion of an oversubscribed $42 million Series B funding round. The fresh capital will enable Nomic to accelerate the expansion of its commercial operations, further invest in advancing its state-of-the-art protein profiling platform, and broaden its transformative offerings to meet growing demand.
This week, Y Combinator (YC) held its Winter 2020 Demo Day, the 30th for the Silicon Valley incubator. To minimize health concerns during the COVID-19 outbreak, YC opted to host the demo day online. For this cohort, 16 Canadian startups participated.
Y Combinator’s Demo Day was a bit different this time around.
Nomic is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Nomic
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$58.4M
Headquarters
Montreal, Canada
Founded
2017
Nomic is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today